Back to discover

Protein / target

RAC-beta serine/threonine-protein kinase

Encoded byAKT2P31751Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
1
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Advanced Clinical

Protein at a glance

Biological role

Protein serine/threonine kinase

Strongest disease association

Hypoinsulinemic hypoglycemia and body hemihypertrophy

Via encoding gene AKT2 · Genetic literature evidence · score 0.84

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Serine/threonine kinase closely related to AKT1 and AKT3.

View complete UniProt function annotation

Serine/threonine kinase closely related to AKT1 and AKT3. All 3 enzymes, AKT1, AKT2 and AKT3, are collectively known as AKT kinase. AKT regulates many processes including metabolism, proliferation, cell survival, growth and angiogenesis, through the phosphorylation of a range of downstream substrates. Over 100 substrates have been reported so far, although for most of them, the precise AKT kinase catalyzing the reaction was not specified. AKT regulates glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT also regulates the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT also regulates cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor 1 (IGF1). AKT mediates the antiapoptotic effects of IGF1. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development (PubMed:21432781, PubMed:21620960). In response to lysophosphatidic acid stimulation, inhibits the ciliogenesis cascade. In this context, phosphorylates WDR44, hence stabilizing its interaction with Rab11 and preventing the formation of the ciliogenic Rab11-FIP3-RAB3IP complex. Also phosphorylates RAB3IP/Rabin8, thus may affect RAB3IP guanine nucleotide exchange factor (GEF) activity toward Rab8, which is important for cilia growth (PubMed:31204173). Phosphorylates PKP1, facilitating its interaction with YWHAG and translocation to the nucleus, ultimately resulting in a reduction in keratinocyte intercellular adhesion (By similarity). Phosphorylation of PKP1 increases PKP1 protein stability, translocation to the cytoplasm away from desmosome plaques and PKP1-driven cap-dependent translation (PubMed:23444369)

Subcellular location

CytoplasmNucleusCell membraneEarly endosome
Domains and Gene Ontology detail (41)

Domains & features

PHProtein kinaseAGC-kinase C-terminal

Gene Ontology

  • Ccell cortex
  • Ccytoplasm
  • Ccytosol
  • Cearly endosome
  • Cnucleoplasm
  • Cnucleus
  • Cplasma membrane
  • Cruffle membrane
  • FATP binding
  • Fmetal ion binding
  • Fmolecular function activator activity
  • Fprotein serine kinase activity

481 aa · 56 kDa · 2 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationUniProt · GOCell proliferation & survivalUniProt · ReactomeLipid & lipoprotein metabolismUniProt · GOSynaptic signallingUniProtReceptor tyrosine kinase signallingReactomeGrowth-factor signallingUniProt
View supporting evidence

Cell migration

  • ·Serine/threonine kinase closely related to AKT1 and AKT3. All 3 enzymes, AKT1, AKT2 and…
  • ·positive regulation of blood vessel endothelial cell migration
  • ·positive regulation of cell migration
  • ·positive regulation of cell motility

Cell proliferation & survival

  • ·Serine/threonine kinase closely related to AKT1 and AKT3. All 3 enzymes, AKT1, AKT2 and…
  • ·PIP3 activates AKT signaling
  • ·CD28 dependent PI3K/Akt signaling

Lipid & lipoprotein metabolism

  • ·Serine/threonine kinase closely related to AKT1 and AKT3. All 3 enzymes, AKT1, AKT2 and…
  • ·negative regulation of long-chain fatty acid import across plasma membrane
  • ·positive regulation of fatty acid beta-oxidation

Synaptic signalling

  • ·Serine/threonine kinase closely related to AKT1 and AKT3. All 3 enzymes, AKT1, AKT2 and…

Receptor tyrosine kinase signalling

  • ·Downregulation of ERBB2:ERBB3 signaling

Growth-factor signalling

  • ·Serine/threonine kinase closely related to AKT1 and AKT3. All 3 enzymes, AKT1, AKT2 and…
View underlying pathways (25)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

PHLPP1TBC1D4AKT1FOXO1PHLPP2PIK3CAPIK3CBFOXO3PIK3R1GSK3BAKT2

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

1 medicine · 2 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Breast Neoplasms1 medicine
Broader indication categories (1)
Neoplasms1 medicine

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

2

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

ipatasertib
Phase 3Inhibitor

Serine/threonine-protein kinase AKT inhibitor

Acts on a complex — shared with AKT3, AKT1 · 1 of 3 recorded protein targets — narrow recorded profile

capivasertib
ApprovedInhibitor

Serine/threonine-protein kinase AKT inhibitor

Indicated for Breast Neoplasms, Neoplasms

Acts on a complex — shared with AKT3, AKT1 · 1 of 3 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene AKT2

Gene-level evidence surfaced through the gene AKT2that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Diabetes Mellitus, Type 2
0.80Well supported

Genetic evidence dominant · Open Targets 0.72

Hypoinsulinemic hypoglycemia and body hemihypertrophy
0.79Well supported

Genetic evidence dominant · Open Targets 0.79

Diabetes Mellitus
0.76Well supported

Genetic literature evidence dominant · Open Targets 0.52

Breast Neoplasms
0.72Moderately supported

Clinical evidence dominant · Open Targets 0.57

AKT2-related familial partial lipodystrophy
0.69Moderately supported

Genetic evidence dominant · Open Targets 0.39

View evidence synthesis (5)
Diabetes Mellitus, Type 2Well supported
0.80
agreement 0.680.92
Genetic67%Animal model24%Literature9%Genetic literaturedup

Open Targets aggregate 0.72 · 3 independent evidence families · 1 not counted as duplicate

Hypoinsulinemic hypoglycemia and body hemihypertrophyWell supported
0.79
agreement 0.670.91
Genetic76%Animal model24%Literature0%Genetic literaturedup

Open Targets aggregate 0.79 · 3 independent evidence families · 1 not counted as duplicate

Diabetes MellitusWell supported
0.76
agreement 0.640.89
Genetic literature63%Animal model25%Literature12%

Open Targets aggregate 0.52 · 3 independent evidence families

Breast NeoplasmsModerately supported
0.72
agreement 0.560.87
Clinical84%Literature16%

Open Targets aggregate 0.57 · 2 independent evidence families

AKT2-related familial partial lipodystrophyModerately supported
0.69
agreement 0.560.81
Genetic75%Animal model25%Genetic literaturedup

Open Targets aggregate 0.39 · 2 independent evidence families · 1 not counted as duplicate

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Hypoinsulinemic hypoglycemia and body hemihypertrophy0.79
Diabetes Mellitus, Type 20.72
Breast Neoplasms0.57
Diabetes Mellitus0.52
Neoplasms0.43
Lung carcinoma0.39
Prostatic Neoplasms0.39
Neurodegenerative Diseases0.39
AKT2-related familial partial lipodystrophy0.39

Drug development

13 compounds recorded · 1 approved · 12 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 2 drugs that target this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (10)
XL-418Phase 1
MIRANSERTIBPhase 2
PIFUSERTIBPhase 2
BAY-1125976Phase 1
TAS0612Phase 1
GSK-690693Phase 1
IPATASERTIBPhase 3
TRICIRIBINE PHOSPHATEPhase 1 2
UPROSERTIBPhase 2
LY-2780301Phase 1 2

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Advanced Clinical and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (literature and uniprot ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (12)
SM · Advanced ClinicalSM · Structure with LigandSM · High-Quality LigandSM · High-Quality PocketSM · Druggable FamilyAB · GO CC high confAB · UniProt loc med confPR · LiteraturePR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

heart diseaseForce et al. (2011)regulation of catalytic activityToxCastIncreased, Liver SteatosisAOP-Wiki

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

RECRUITING · via capivasertib · NCT07294677

RECRUITING · via ipatasertib · NCT05564377

ACTIVE_NOT_RECRUITING · via ipatasertib · NCT06400251

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 2 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Indication expanded2026-06-12

    Indication expansion: CAPIVASERTIB (NDA218197)

    fda · regulatory · fda · via capivasertib

  2. Label change2026-05-27

    Label change: CAPIVASERTIB (NDA218197)

    fda · regulatory · fda · via capivasertib

  3. Label change2025-11-14

    Label change: CAPIVASERTIB (NDA218197)

    fda · regulatory · fda · via capivasertib

  4. Label change2025-02-13

    Label change: CAPIVASERTIB (NDA218197)

    fda · regulatory · fda · via capivasertib

  5. Label change2024-09-23

    Label change: CAPIVASERTIB (NDA218197)

    fda · regulatory · fda · via capivasertib

  6. Regulatory approval2024-06-17

    Approval: Truqap (EMA)

    ema · regulatory · ema · via capivasertib

  7. New publication2024-04-02
    Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer.

    The Annals of pharmacotherapy · 2024 · 18 citations · Europe PMC · via capivasertib

  8. New publication2024-02-01
    First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.

    Clinical cancer research : an official journal of the American Association for Cancer Research · 2024 · 35 citations · Europe PMC · via ipatasertib

  9. Regulatory approval2023-11-16

    Approval: CAPIVASERTIB (NDA218197)

    fda · regulatory · fda · via capivasertib

  10. New publication2023-06-01
    Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.

    The New England journal of medicine · 2023 · 539 citations · Europe PMC · via capivasertib

  11. New publication2020-09-10
    Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.

    The Lancet. Oncology · 2020 · 274 citations · Europe PMC · via capivasertib

  12. New publication2019-12-16
    Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020 · 304 citations · Europe PMC · via capivasertib

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.